Comparative Pharmacology
Head-to-head clinical analysis: FINASTERIDE AND TADALAFIL versus STAXYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINASTERIDE AND TADALAFIL versus STAXYN.
FINASTERIDE AND TADALAFIL vs STAXYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Finasteride is a 5α-reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT). Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor that enhances nitric oxide-mediated vasodilation by increasing cyclic guanosine monophosphate (cGMP) in smooth muscle.
Selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). By inhibiting PDE5, sildenafil increases intracellular cGMP levels in the corpus cavernosum, enhancing the relaxant effect of nitric oxide (NO) on smooth muscle cells, thereby facilitating penile erection in response to sexual stimulation.
One capsule containing finasteride 5 mg and tadalafil 5 mg orally once daily.
10 mg sublingually as needed, 30–60 minutes before sexual activity. Maximum 1 dose per 24 hours.
None Documented
None Documented
Finasteride: 6-8 hours (elderly ~8 hours); Tadalafil: 17.5 hours (enables once-daily dosing).
Terminal elimination half-life is approximately 4-5 hours; clinically, no accumulation with once-daily dosing
Finasteride: 57% feces, 39% urine (metabolites); Tadalafil: 36% urine, 61% feces (mostly metabolites).
Renal (approximately 90% as metabolites, <2% unchanged); fecal (10%)
Category A/B
Category C
PDE5 Inhibitor
PDE5 Inhibitor